NCT01803282 2020-06-02
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Completed
Gilead Sciences
Eli Lilly and Company
M.D. Anderson Cancer Center
Fudan University
National Institutes of Health Clinical Center (CC)